Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Idogen

NGM:IDOGEN
Snowflake Description

Exceptional growth potential and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IDOGEN
NGM
SEK27M
Market Cap
  1. Home
  2. SE
  3. Pharmaceuticals & Biotech
Company description

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, or the body’s own cells or tissues in Sweden. The last earnings update was 66 days ago. More info.


Add to Portfolio Compare Print
  • Idogen has significant price volatility in the past 3 months.
IDOGEN Share Price and Events
7 Day Returns
-2.1%
NGM:IDOGEN
7.3%
SE Biotechs
0.3%
SE Market
1 Year Returns
-3.8%
NGM:IDOGEN
-28.6%
SE Biotechs
-13.2%
SE Market
IDOGEN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Idogen (IDOGEN) -2.1% -19.1% -40% -3.8% -93.6% -
SE Biotechs 7.3% -4.7% -7.5% -28.6% 4.7% 35.5%
SE Market 0.3% -19.3% -23.1% -13.2% -14.7% -16.1%
1 Year Return vs Industry and Market
  • IDOGEN outperformed the Biotechs industry which returned -28.6% over the past year.
  • IDOGEN outperformed the Market in Sweden which returned -13.2% over the past year.
Price Volatility
IDOGEN
Industry
5yr Volatility vs Market

Value

 Is Idogen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Idogen to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Idogen.

NGM:IDOGEN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.7%
Perpetual Growth Rate 10-Year SE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NGM:IDOGEN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year SE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.189 (1 + (1- 22%) (0%))
1.127
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.42% + (1.127 * 5.44%)
5.71%

Discounted Cash Flow Calculation for NGM:IDOGEN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Idogen is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NGM:IDOGEN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 5.71%)
2020 -33.00 Analyst x1 -31.22
2021 -34.50 Analyst x2 -30.87
2022 11.00 Analyst x1 9.31
2023 14.88 Est @ 35.29% 11.92
2024 18.54 Est @ 24.58% 14.05
2025 21.71 Est @ 17.08% 15.56
2026 24.27 Est @ 11.83% 16.46
2027 26.25 Est @ 8.15% 16.84
2028 27.72 Est @ 5.58% 16.82
2029 28.77 Est @ 3.78% 16.51
Present value of next 10 years cash flows SEK55.00
NGM:IDOGEN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= SEK28.77 × (1 + -0.42%) ÷ (5.71% – -0.42%)
SEK467.39
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK467.39 ÷ (1 + 5.71%)10
SEK268.26
NGM:IDOGEN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK55.00 + SEK268.26
SEK323.26
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK323.26 / 48.49
SEK6.67
NGM:IDOGEN Discount to Share Price
Calculation Result
Value per share (SEK) From above. SEK6.67
Current discount Discount to share price of SEK0.55
= -1 x (SEK0.55 - SEK6.67) / SEK6.67
91.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Idogen is available for.
Intrinsic value
>50%
Share price is SEK0.55 vs Future cash flow value of SEK6.67
Current Discount Checks
For Idogen to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Idogen's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Idogen's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Idogen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Idogen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NGM:IDOGEN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK-0.67
NGM:IDOGEN Share Price ** NGM (2020-04-03) in SEK SEK0.55
Sweden Biotechs Industry PE Ratio Median Figure of 6 Publicly-Listed Biotechs Companies 40.49x
Sweden Market PE Ratio Median Figure of 356 Publicly-Listed Companies 14.42x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Idogen.

NGM:IDOGEN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NGM:IDOGEN Share Price ÷ EPS (both in SEK)

= 0.55 ÷ -0.67

-0.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Idogen is loss making, we can't compare its value to the SE Biotechs industry average.
  • Idogen is loss making, we can't compare the value of its earnings to the Sweden market.
Price based on expected Growth
Does Idogen's expected growth come at a high price?
Raw Data
NGM:IDOGEN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
37.6%per year
Sweden Biotechs Industry PEG Ratio Median Figure of 6 Publicly-Listed Biotechs Companies 1.42x
Sweden Market PEG Ratio Median Figure of 234 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Idogen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Idogen's assets?
Raw Data
NGM:IDOGEN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK0.38
NGM:IDOGEN Share Price * NGM (2020-04-03) in SEK SEK0.55
Sweden Biotechs Industry PB Ratio Median Figure of 54 Publicly-Listed Biotechs Companies 3.31x
Sweden Market PB Ratio Median Figure of 772 Publicly-Listed Companies 2.13x
NGM:IDOGEN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NGM:IDOGEN Share Price ÷ Book Value per Share (both in SEK)

= 0.55 ÷ 0.38

1.46x

* Primary Listing of Idogen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Idogen is good value based on assets compared to the SE Biotechs industry average.
X
Value checks
We assess Idogen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Idogen has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Idogen expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Idogen expected to grow at an attractive rate?
  • Idogen's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Idogen's earnings growth is expected to exceed the Sweden market average.
  • Idogen's revenue growth is expected to exceed the Sweden market average.
Annual Growth Rates Comparison
Raw Data
NGM:IDOGEN Future Growth Rates Data Sources
Data Point Source Value (per year)
NGM:IDOGEN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 37.6%
NGM:IDOGEN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 74.8%
Sweden Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 15.7%
Sweden Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 9.1%
Sweden Market Earnings Growth Rate Market Cap Weighted Average 8.3%
Sweden Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NGM:IDOGEN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NGM:IDOGEN Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 58 18 13 1
2021-12-31 0 -19 -33 2
2020-12-31 0 -27 -31 1
2020-04-04
NGM:IDOGEN Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 4 -35 -33
2019-09-30 7 -28 -29
2019-06-30 6 -26 -30
2019-03-31 5 -27 -27
2018-12-31 4 -10 -28
2018-09-30 -18 -30
2018-06-30 -19 -29
2018-03-31 -12 -25
2017-12-31 -20 -21
2017-09-30 0 -15 -18
2017-06-30 0 -9 -14
2017-03-31 0 -12 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Idogen's earnings are expected to grow significantly at over 20% yearly.
  • Idogen's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NGM:IDOGEN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Idogen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NGM:IDOGEN Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 0.13 0.13 0.13 1.00
2021-12-31 -0.55 -0.22 -0.89 2.00
2020-12-31 -0.43 -0.43 -0.43 1.00
2020-04-04
NGM:IDOGEN Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 -0.67
2019-09-30 -0.69
2019-06-30 -0.84
2019-03-31 -0.95
2018-12-31 -1.27
2018-09-30 -1.45
2018-06-30 -1.41
2018-03-31 -1.36
2017-12-31 -1.32
2017-09-30 -1.31
2017-06-30 -1.25
2017-03-31 -1.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Idogen is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Idogen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Sweden market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Sweden market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Idogen has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Idogen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Idogen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Idogen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Idogen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Idogen's 1-year growth to the SE Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Idogen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Idogen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NGM:IDOGEN Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 4.19 -32.69 31.12
2019-09-30 6.73 -29.29 30.49
2019-06-30 5.76 -29.99 30.11
2019-03-31 4.62 -27.45 31.00
2018-12-31 3.77 -27.63 30.64
2018-09-30 -30.14 29.59
2018-06-30 -28.89 28.65
2018-03-31 -24.89 24.87
2017-12-31 -21.32 21.22
2017-09-30 0.00 -18.26 24.93
2017-06-30 0.00 -14.43 19.26
2017-03-31 0.01 -13.19 13.18
2016-12-31 0.05 -12.60 12.64
2016-09-30 0.09 -11.89 10.37
2016-06-30 0.18 -11.69 10.42
2016-03-31 0.26 -10.24 12.38
2015-12-31 0.34 -9.66 10.00
2015-09-30 0.42 -7.79 1.77
2014-12-31 0.31 -1.95 0.81
2013-12-31 0.20 -0.04

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Idogen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Idogen has efficiently used its assets last year compared to the SE Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Idogen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Idogen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Idogen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Idogen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Idogen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Idogen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Idogen's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Idogen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Idogen has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Idogen Company Filings, last reported 3 months ago.

NGM:IDOGEN Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 18.33 0.00 26.00
2019-09-30 26.54 0.00 33.80
2019-06-30 33.16 0.00 42.42
2019-03-31 44.37 0.00 49.09
2018-12-31 51.02 0.00 61.60
2018-09-30 17.08 0.00 23.75
2018-06-30 24.40 0.00 31.62
2018-03-31 33.05 0.00 39.90
2017-12-31 39.89 0.00 36.94
2017-09-30 47.20 0.00 47.90
2017-06-30 5.95 0.00 8.76
2017-03-31 14.56 0.00 14.96
2016-12-31 18.60 0.00 18.50
2016-09-30 3.76 0.00 2.60
2016-06-30 6.06 0.00 4.99
2016-03-31 9.48 0.00 9.17
2015-12-31 12.17 0.00 11.54
2015-09-30 15.72 0.00 15.16
2014-12-31 3.45 0.00 3.04
2013-12-31 0.40 0.00 0.03
  • Idogen has no debt.
  • Idogen has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Idogen has less than a year of cash runway based on current free cash flow.
  • Idogen has less than a year of cash runway if free cash flow continues to grow at historical rates of 32.4% each year.
X
Financial health checks
We assess Idogen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Idogen has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Idogen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Idogen dividends.
If you bought SEK2,000 of Idogen shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Idogen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Idogen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NGM:IDOGEN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Sweden Market Average Dividend Yield Market Cap Weighted Average of 224 Stocks 4%
Sweden Minimum Threshold Dividend Yield 10th Percentile 1%
Sweden Bottom 25% Dividend Yield 25th Percentile 2.1%
Sweden Top 25% Dividend Yield 75th Percentile 6.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NGM:IDOGEN Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-04

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Idogen has not reported any payouts.
  • Unable to verify if Idogen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Idogen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Idogen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Idogen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Idogen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Idogen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Idogen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anders Karlsson
AGE 55
TENURE AS CEO 0.7 years
CEO Bio

Mr. Anders Karlsson, M.B.A., has been Chief Executive Officer of Idogen AB (publ) since August 19, 2019. Mr. Karlsson served as the Chairman of the Board and Chief Executive Officer of Olerup Inc. Mr. Karlsson was the Chief International Business Officer at CareDx, Inc. since April 2016. Mr. Karlsson was National Director of Russia at Valeo SA since November 2012 until September 2018. Mr. Karlsson served as the Chief Executive Officer of Olerup SSP AB. He served as the Chief Executive Officer of AbSorber AB from April 17, 2008 to 2009 and also served as its Chief Operating Officer since September 2007. He served as the Chief Executive Officer of Allenex AB (publ) since May 25, 2011 and Olerup International AB from 2009 to 2011. He has more than 20 years of experience in the pharmaceutical industry, including sales person and Sales Director at Sandoz, Marketing Manager and Sales & Marketing Director at Novartis Sverige AB. He has held several positions including Head of Sales, Head of Sales and Marketing and also served as the Chief Executive Officer and President for operations in Norway at Novartis Norge AS. He served as a Director of Sales for the transplantation business area at Sandoz. He served as a Director of Olerup SSP AB. Mr. Karlsson studied economics at University of Jönköping and marketing management at IHM Business School Linköping. Mr. Karlsson received M.B.A. from the Henley Business School of the University of Reading, United Kingdom.

CEO Compensation
  • Insufficient data for Anders to compare compensation growth.
  • Insufficient data for Anders to establish whether their remuneration is reasonable compared to companies of similar size in Sweden.
Management Team Tenure

Average tenure and age of the Idogen management team in years:

2.9
Average Tenure
55
Average Age
  • The tenure for the Idogen management team is about average.
Management Team

Anders Karlsson

TITLE
Chief Executive Officer
AGE
55
TENURE
0.7 yrs

Ingvar Karlsson

TITLE
Chief Financial Officer
AGE
63
TENURE
3.9 yrs

Dennis Henriksen

TITLE
Chief Technology Officer
COMPENSATION
SEK121K
AGE
57
TENURE
5.3 yrs

Hanne Romedahl

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board
AGE
48
TENURE
1.9 yrs

Terese Hylander

TITLE
Project & Communications Manager
TENURE
1.3 yrs

Neil Thomas

TITLE
CBO & Patent Manager
COMPENSATION
SEK84K
AGE
48
TENURE
5.3 yrs
Board of Directors Tenure

Average tenure and age of the Idogen board of directors in years:

3.9
Average Tenure
55
Average Age
  • The tenure for the Idogen board of directors is about average.
Board of Directors

Agneta Edberg

TITLE
Chairman of The Board
AGE
63
TENURE
4 yrs

Hanne Romedahl

TITLE
Chief Scientific Officer & Member of Scientific Advisory Board
AGE
48
TENURE
2.3 yrs

Leif Salford

TITLE
Chairman of the Scientific Advisory Board & Director
AGE
78
TENURE
4.6 yrs

Rolf Ljung

TITLE
Member of Scientific Advisory Board
TENURE
4.5 yrs

Hans-Olov Sjögren

TITLE
Member of Scientific Advisory Board

Richard Williams

TITLE
Member of Scientific Advisory Board
TENURE
4.5 yrs

Anette Sundstedt

TITLE
Member of Scientific Advisory Board
AGE
52
TENURE
3.8 yrs

Christina Herder

TITLE
Director
AGE
58
TENURE
2.9 yrs

Karin Hoogendoorn

TITLE
Director
AGE
49
TENURE
2.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
04. Jul 19 Sell Erika Samuelsson Individual 04. Jul 19 04. Jul 19 -31,429 SEK2.30 SEK-72,243
X
Management checks
We assess Idogen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Idogen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, or the body’s own cells or tissues in Sweden. Its advanced product candidate is IDO 8, designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII. The company also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection, primarily kidney transplant rejection. The company was founded in 2008 and is headquartered in Lund, Sweden.

Details
Name: Idogen AB (publ)
IDOGEN
Exchange: NGM
Founded: 2008
SEK26,670,343
48,491,533
Website: http://www.idogen.com
Address: Idogen AB (publ)
Medicon Village,
Scheelevägen 2,
Lund,
Skåne County, 223 81,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NGM IDOGEN Share Capital Nordic Growth Market SE SEK 12. Jun 2015
NGM IDOGEN BTA NPV BTA 052020 Nordic Growth Market SE SEK 04. Apr 2020
Number of employees
Current staff
Staff numbers
10
Idogen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 20:03
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/01/29
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.